Digestive Disease Week

Digestive Disease Week

Source:

Sayuk G, et al. Poster Fr437. Presented at: Digestive Disease Week; May 21-23, 2021 (virtual meeting).

Disclosures: Sayuk reports speaking/teaching as well as serving on advisory committees for AbbVie, Alnylam, Ironwood and Salix. Please see the study for all other authors’ relevant financial disclosures.
May 26, 2021
1 min watch
Save

VIDEO: Trulance improves quality of life for those with constipation

Source:

Sayuk G, et al. Poster Fr437. Presented at: Digestive Disease Week; May 21-23, 2021 (virtual meeting).

Disclosures: Sayuk reports speaking/teaching as well as serving on advisory committees for AbbVie, Alnylam, Ironwood and Salix. Please see the study for all other authors’ relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Trulance improved quality of life among patients with irritable bowel syndrome and chronic constipation, Greg Sayuk, MD, MPH, Washington University at St. Louis, told Healio.

Trulance (plecanatide, Salix) previously demonstrated clinical efficacy with a benign safety and tolerability profile within four clinical trials and is approved for the treatment of adults with chronic constipation and IBS-C. In a post-hoc analysis, researchers aimed to further analyzed the impact of plecanatide on the quality of life in patients with chronic constipation (n = 1,762) and IBS-C (n = 1,453) who had the lowest quality of life measures at baseline.

Compared with placebo, plecanatide 3 mg demonstrated greater overall improvement in quality of life scores from baseline in patients with chronic constipation (1.4 vs. 1.7) and patients with IBS-C (81.9 vs. 80.4) at 12-weeks. Sayuk and colleagues also noted plecanatide significantly improved satisfaction and worries/concerns as well as dysphoria, body image, social reaction and relationship items.

“This study really highlights and informs us that these medications have a broader impact on the well-being of the individuals, for certain, but also their ability to engage in in the workplace and social activities,” Sayuk said. “There's really a broader potential beyond just improvement in the bowel patterns for the individual.”